EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC

Andrew W Hahn, Nabil Adra, Ulka Vaishampayan, Lianchun Xiao, Nazli Dizman, Ying Yuan iD, Sagar S Mukhida, Matthew T Campbell, Jianjun Gao iD, Amado J Zurita, Eric Jonasch iD, Nizar M Tannir und 2 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf053 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2025. Verfasst von Andrew W Hahn und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Texas MD Anderson Cancer Center, Mirati Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC). ICI is the standard first-line (1L) treatment of metastatic ccRCC, and there is unmet need for improved treatment outcomes after progression on ICI. We hypothesized that sitravatinib plus nivolumab would revert an immunosuppressive tumor microenvironment (TME) to improve clinical outcomes.

Methods

In this investigator-initiated, phase II, multicenter trial (NCT04904302), patients with progressive metastatic ccRCC after 1-2 lines of treatment were enrolled into 3 cohorts: (1) 1L nivolumab + ipilimumab, (2) 1L pembrolizumab + axitinib, (3) prior cabozantinib or lenvatinib and ICI. Starting dose of sitravatinib was 100 mg PO daily and nivolumab was 480 mg IV every 4 weeks. The co-primary endpoints were objective response rate (ORR) and disease control rate (DCR) at 24 weeks. The study was designed to enroll 88 patients with an interim analysis for futility in each cohort using a BOP2 design, but it was terminated early due to discontinuation of sitravatinib development.

Results

Fourteen patients were enrolled with 2 in cohort A, 6 in cohort B, and 6 in cohort C. Across all cohorts, the ORR was 15.4% (2/13, 1 not evaluable) and DCR at 24 weeks was 35.7% (5/14). DCR at 24 months was 63% for Cohort A + B and 0% for Cohort C. Median progression free survival was 5.5 mo [95% CI 3.8—not reached (NR)], and median overall survival was 13.3 mo (95% CI 8.77—NR). Six patients (42.9%) experienced a grade 3-4 adverse event (AE) and 2 patients (14.3%) experienced an immune-mediated AE.

Conclusion

In this small phase 2 trial with limited sample size due to early termination, sitravatinib plus nivolumab demonstrated a manageable safety profile and produced modest clinical benefit. The observed responses occurred in patients who did not receive prior treatment with cabozantinib or lenvatinib. (ClinicalTrials.gov Identifier: NCT04904302).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCarcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedAdultDisease ProgressionAged, 80 and over

Stichwörter der Autor:innen

MET inhibitorTAMimmunotherapy rechallengetargeted therapy

Substanzen

NivolumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Division of Hematology/Oncology, Department of Internal Medicine, Indiana University, Indianapolis, IN 46202, United States.
  • Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109,United States.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

ORCID-Profile: Ying Yuan, Jianjun Gao, Eric Jonasch, Pavlos Msaouel

Förderung

  • The University of Texas MD Anderson Cancer Center
  • Mirati Therapeutics

Zitieren

APA

Hahn, A. W., Adra, N., Vaishampayan, U., Xiao, L., Dizman, N., Yuan, Y., Mukhida, S. S., Campbell, M. T., Gao, J., Zurita, A. J., Jonasch, E., Tannir, N. M., Shah, A. Y., & Msaouel, P. (2025). A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC. The Oncologist. https://doi.org/10.1093/oncolo/oyaf053

Vancouver

Hahn AW, Adra N, Vaishampayan U, Xiao L, Dizman N, Yuan Y, et al. A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC. The Oncologist. 2025. doi:10.1093/oncolo/oyaf053

BibTeX
@article{Hahn2025,
  author = {Hahn, Andrew W and Adra, Nabil and Vaishampayan, Ulka and Xiao, Lianchun and Dizman, Nazli and Yuan, Ying and Mukhida, Sagar S and Campbell, Matthew T and Gao, Jianjun and Zurita, Amado J and Jonasch, Eric and Tannir, Nizar M and Shah, Amishi Y and Msaouel, Pavlos},
  title = {A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf053}
}
Kostenlos starten →